Standard Chartered analyst apologizes for $120,000 bitcoin price call, says target ‘may be too low’

Standard Chartered analyst apologizes for 0,000 bitcoin price call, says target ‘may be too low’


Vcg | Visual China Group | Getty Images

A Standard Chartered analyst who predicted bitcoin hitting $120,000 by the second quarter now says his price call is “too low.”

“I apologise that my USD120k Q2 target may be too low,” Geoffrey Kendrick, head of digital assets at Standard Chartered, said in a tongue-in-cheek comment shared with clients via email Thursday.

Last month, Kendrick wrote a note saying that he expects bitcoin to reach an all-time high of around $120,000 in the second quarter of 2025 on the back of a “strategic asset reallocation away from US assets” and “accumulation by ‘whales’ (major holders).”

“We expect these supportive factors to push BTC to a fresh all-time high around USD 120,000 in Q2,” Kendrick said at the time. “We see gains continuing through the summer, taking BTC-USD towards our year-end forecast of 200,000.”

On Thursday, Kendrick said his $120,000 bitcoin price call now “looks very achievable” and that this may even be too low a target.

“The dominant story for Bitcoin has changed again,” the Standard Chartered analyst said. “It was correlation to risk assets … It then became a way to position for strategic asset reallocation out of US assets.”

“It is now all about flows. And flows are coming in many forms,” he added.

His comments come as bitcoin once again approaches the $100,000 level. The price of the cryptocurrency was last seen trading up by more than 3% at $99,293.54, according to Coin Metrics. Earlier, it rose as high as $99,897.00.

In recent years, analysts have picked up on a pattern that shows bitcoin trading in a similar way to risk assets such as U.S. technology stocks — the rationale being that increased inflows of more institutional capital into bitcoin makes it more prone to the same market risks equity markets face.

Bitcoin rises as Fed leaves rates unchanged: CNBC Crypto World

Kendrick — who has long held a bullish position on the cryptocurrency — said that U.S. spot bitcoin exchange-traded funds have seen $5.3 billion of inflows in the past three weeks, suggesting more institutional money is piling in.

He pointed to several examples of large investors allocating part of their portfolios to bitcoin, including software firm MicroStrategy ramping up bitcoin purchases, the Abu Dhbai sovereign wealth fund holding BlackRock’s IBIT bitcoin ETF, and the Swiss National Bank buying shares of MicroStrategy.

MicroStrategy is widely considered a proxy for bitcoin.



Source

Payrolls rose by 64,000 in November after falling by 105,000 in October, delayed jobs numbers show
World

Payrolls rose by 64,000 in November after falling by 105,000 in October, delayed jobs numbers show

A “Help Wanted” sign hangs in a restaurant window in Medford, Massachusetts, Jan. 25, 2023. Brian Snyder | Reuters Nonfarm payrolls grew slightly more than expected in November but slumped in October while unemployment hit its highest in four years, the Bureau of Labor Statistics reported Tuesday in numbers delayed by the government shutdown. Job […]

Read More
Oil prices tumble to lowest since May, on pace for biggest annual decline in 7 years
World

Oil prices tumble to lowest since May, on pace for biggest annual decline in 7 years

Oil prices held on to most gains from the previous session in early trading on Thursday as investors awaited U.S.-China trade talks later in the day. Anton Petrus | Moment | Getty Images U.S. crude oil on Tuesday hit the lowest level since May, putting prices on pace for the worst performance in seven years […]

Read More
Europe’s best-performing stock is up 1,400% this year. Here’s what’s next
World

Europe’s best-performing stock is up 1,400% this year. Here’s what’s next

Key Points Abivax shares are up more than 1,400% year to date as investors are optimistic about the prospects of its treatment for ulcerative colitis.  “We are certainly excited about the work we are doing, and we’ve been greeted again by the medical community as becoming possibly this next standard of care in ulcerative colitis,” […]

Read More